Latest press releases
- European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer
- 21 February 2012
- AstraZeneca’s new restructuring initiatives to drive productivity and support innovation
- 2 February 2012
- AstraZeneca PLC Fourth quarter and full year results 2011
- 2 February 2012
- AstraZeneca and Bristol-Myers Squibb receive complete response letter from US Food and Drug Administration for dapagliflozin
- 19 January 2012
- AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- 11 January 2012
- AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period
- 9 January 2012
- AstraZeneca updates on olaparib and TC-5214 development programmes
- 20 December 2011
- G-BA issues positive final medical benefit assessment for BRILIQUE in Germany
- 15 December 2011
- AstraZeneca to acquire generics company to broaden patient access to medicines in China
- 8 December 2011
Annual information update
This update relates to information that has been published or made available to the public between 09 April 2010 and 7 April 2011.
Annual update 2011 (PDF 110kb)
Currency guidance
Financial results
Fourth quarter and full year results 2011 announced Thursday, 2 February 2012.
Latest presentations
February 2012
January 2012
Simon Lowth (Chief Financial Officer) presented at the J.P. Morgan Annual Healthcare Conference in San Francisco.
30th Annual J.P. Morgan Healthcare Conference (PDF 1335kb)Annual Report 2010
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and make a meaningful difference for patients worldwide.